调节磷稳态的骨-肾轴的证据。
Evidence for a bone-kidney axis regulating phosphate homeostasis.
作者信息
Quarles L Darryl
机构信息
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
出版信息
J Clin Invest. 2003 Sep;112(5):642-6. doi: 10.1172/JCI19687.
Abstract
A novel circulation phosphaturic hormone is postulated to regulate systemic phosphate homeostasis. Two new studies reveal that the phosphaturic factor FGF-23 is increased in hypophosphatemic subjects with McCune-Albright syndrome and that secreted frizzled-related protein-4 (sFRP-4), a factor produced by tumors derived from subjects with tumor-induced osteomalacia, also has phosphaturic activity. It remains to be established whether FGF-23 and sFRP-4 represent two distinct phosphatonins or are somehow integrated in a novel phosphate-regulating bone-kidney axis.
摘要
一种新型的循环磷尿激素被推测可调节全身磷酸盐稳态。两项新研究表明，在患有McCune-Albright综合征的低磷血症患者中，磷尿因子FGF-23水平升高，并且来自肿瘤诱导骨软化症患者的肿瘤产生的因子——分泌型卷曲相关蛋白4（sFRP-4）也具有磷尿活性。FGF-23和sFRP-4是代表两种不同的磷调节素，还是以某种方式整合在一种新型的磷酸盐调节骨-肾轴中，仍有待确定。
相似文献
1
Evidence for a bone-kidney axis regulating phosphate homeostasis.调节磷稳态的骨-肾轴的证据。
J Clin Invest. 2003 Sep;112(5):642-6. doi: 10.1172/JCI19687.
2
ASARM mineralization hypothesis: a bridge too far?ASARM矿化假说：跨度太大？
J Bone Miner Res. 2010 Apr;25(4):692-4. doi: 10.1002/jbmr.69.
3
The phosphatonins and the regulation of phosphate homeostasis.
Ann Endocrinol (Paris). 2006 Apr;67(2):142-6. doi: 10.1016/s0003-4266(06)72570-7.
4
[Assessment of bone quality. Osteocyte function and bone quality].[骨质量评估。骨细胞功能与骨质量]
Clin Calcium. 2008 Mar;18(3):321-5.
5
[Bone and tooth in calcium and phosphate metabolism].[钙和磷代谢中的骨骼与牙齿]
Clin Calcium. 2012 Jan;22(1):11-7.
6
FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.成纤维细胞生长因子23（FGF23）、磷酸盐调节基因同源物（PHEX）和基质细胞外磷酸糖蛋白（MEPE）对磷稳态及骨骼矿化的调节
Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E1-9. doi: 10.1152/ajpendo.00016.2003.
7
Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis.牙本质基质蛋白1（DMP1）：生物矿化和磷酸盐稳态的新的重要作用。
J Dent Res. 2007 Dec;86(12):1134-41. doi: 10.1177/154405910708601202.
8
Do osteocytes contribute to phosphate homeostasis?骨细胞对磷酸盐稳态有贡献吗？
Curr Opin Nephrol Hypertens. 2009 Jul;18(4):285-91. doi: 10.1097/MNH.0b013e32832c224f.
9
Bone talk.骨语。
Nat Genet. 2006 Nov;38(11):1230-1. doi: 10.1038/ng1106-1230.
10
Hypophosphatemia: an update on its etiology and treatment.低磷血症：病因与治疗的最新进展
Am J Med. 2005 Oct;118(10):1094-101. doi: 10.1016/j.amjmed.2005.02.014.
引用本文的文献
1
FGF-based drug discovery: advances and challenges.基于成纤维细胞生长因子（FGF）的药物研发：进展与挑战
Nat Rev Drug Discov. 2025 May;24(5):335-357. doi: 10.1038/s41573-024-01125-w. Epub 2025 Jan 28.
2
Phosphorus: Chronicles of the epistemology of a vital element.磷：生命元素认识论的编年史。
Clin Nephrol. 2024 Sep;102(3):117-124. doi: 10.5414/CN111435.
3
Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to α-Klotho.通过计算热点预测和与 α-Klotho 的分子对接鉴定成纤维细胞生长因子 23 信号的小分子抑制剂。
J Chem Inf Model. 2022 Aug 8;62(15):3627-3637. doi: 10.1021/acs.jcim.2c00633. Epub 2022 Jul 22.
4
Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Mice.新型小分子成纤维细胞生长因子 23 抑制剂增加血清磷酸盐并改善小鼠的骨骼异常。
Mol Pharmacol. 2021 Jun;101(6):408-421. doi: 10.1124/molpharm.121.000471. Epub 2022 Mar 26.
5
The Saga of Endocrine FGFs.内分泌 FGFs 的传奇。
Cells. 2021 Sep 14;10(9):2418. doi: 10.3390/cells10092418.
6
Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues.成纤维细胞生长因子 23 拮抗剂的设计与开发：通过合成类似物探测药效团和初步结构活性关系的定义。
Bioorg Med Chem. 2021 Jan 1;29:115877. doi: 10.1016/j.bmc.2020.115877. Epub 2020 Nov 18.
7
Higher Fibroblast Growth Factor 23 Levels Are Causally Associated With Lower Bone Mineral Density of Heel and Femoral Neck: Evidence From Two-Sample Mendelian Randomization Analysis.成纤维细胞生长因子23水平升高与足跟和股骨颈骨密度降低存在因果关联：来自两样本孟德尔随机化分析的证据
Front Public Health. 2020 Sep 2;8:467. doi: 10.3389/fpubh.2020.00467. eCollection 2020.
8
Linear and Non-linear Correlations Between Serum Phosphate Level and Bone Mineral Density in Type 2 Diabetes.血清磷酸盐水平与 2 型糖尿病患者骨密度的线性和非线性相关性。
Front Endocrinol (Lausanne). 2020 Jul 30;11:497. doi: 10.3389/fendo.2020.00497. eCollection 2020.
9
Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.磷稳态的分子调控与低磷血症性疾病的精准治疗
Curr Mol Biol Rep. 2019 Jun;5(2):75-85. doi: 10.1007/s40610-019-0118-1. Epub 2019 Feb 9.
10
ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1.ENPP1，一种具有新功能的老酶，以及小分子抑制剂——ENPP1 故事中的 STING。
Molecules. 2019 Nov 19;24(22):4192. doi: 10.3390/molecules24224192.
本文引用的文献
1
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.分泌型卷曲相关蛋白4是一种强效的肿瘤源性排磷因子。
J Clin Invest. 2003 Sep;112(5):785-94. doi: 10.1172/JCI18563.
2
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.骨纤维异常增殖症中的成纤维细胞生长因子-23及其与肾性磷酸盐消耗的关系。
J Clin Invest. 2003 Sep;112(5):683-92. doi: 10.1172/JCI18399.
3
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.成纤维细胞生长因子23表达的调控，而非PHEX对其降解的调控。
J Biol Chem. 2003 Sep 26;278(39):37419-26. doi: 10.1074/jbc.M304544200. Epub 2003 Jul 21.
4
Serum FGF23 levels in normal and disordered phosphorus homeostasis.正常和紊乱的磷稳态中的血清成纤维细胞生长因子23水平。
J Bone Miner Res. 2003 Jul;18(7):1227-34. doi: 10.1359/jbmr.2003.18.7.1227.
5
Evidence for the proteolytic processing of dentin matrix protein 1. Identification and characterization of processed fragments and cleavage sites.牙本质基质蛋白1蛋白水解加工的证据。加工片段和切割位点的鉴定与表征。
J Biol Chem. 2003 Sep 5;278(36):34700-8. doi: 10.1074/jbc.M305315200. Epub 2003 Jun 17.
6
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.成骨细胞骨软化症和X连锁低磷血症中的成纤维细胞生长因子23
N Engl J Med. 2003 Apr 24;348(17):1656-63. doi: 10.1056/NEJMoa020881.
7
Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.成骨细胞/骨细胞因子45基因（OF45）的靶向破坏导致骨形成增加和骨量增加。
J Biol Chem. 2003 Jan 17;278(3):1998-2007. doi: 10.1074/jbc.M203250200. Epub 2002 Nov 5.
8
Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.人成纤维细胞生长因子-23突变体抑制钠依赖性磷酸盐共转运活性和1α,25-二羟基维生素D3的产生。
J Biol Chem. 2003 Jan 24;278(4):2206-11. doi: 10.1074/jbc.M207872200. Epub 2002 Nov 4.
9
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.低磷性佝偻病/骨软化症患者体内具有生物活性的全长成纤维细胞生长因子23（FGF-23）循环水平升高。
J Clin Endocrinol Metab. 2002 Nov;87(11):4957-60. doi: 10.1210/jc.2002-021105.
10
Inhibition of MEPE cleavage by Phex.Phex对MEPE裂解的抑制作用。
Biochem Biophys Res Commun. 2002 Sep 13;297(1):38-45. doi: 10.1016/s0006-291x(02)02125-3.
Zotero 插件